Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
about
Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case seriesTelmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney diseaseInvolvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.New and emerging strategies for reducing cardiometabolic risk factors.Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.Thiazolidinediones: effects on insulin resistance and the cardiovascular system.Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.PPARgamma Agonists: Potential as Therapeutics for Neovascular RetinopathiesMetabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?Present and future therapeutic strategies in non-alcoholic fatty liver disease.Candesartan cilexetil prevents diet-induced insulin resistance via peroxisome proliferator-activated receptor-γ activation in an obese rat model.The basis of an intracrine pharmacology.Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY).Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease.Escherichia coli K1 Modulates Peroxisome Proliferator-Activated Receptor γ and Glucose Transporter 1 at the Blood-Brain Barrier in Neonatal Meningitis.Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure.Effects of germinated brown rice and its bioactive compounds on the expression of the peroxisome proliferator-activated receptor gamma gene.Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension.Effect of telmisartan on the expression of adiponectin receptors and nicotinamide adenine dinucleotide phosphate oxidase in the heart and aorta in type 2 diabetic ratsRenin-angiotensin system activation in renal adipogenesis.Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial.Relationship between telmisartan dose and glycaemic control in Japanese patients with type 2 diabetes mellitus and hypertension: a retrospective study.A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation.Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study.Effect of telmisartan on the expression of cardiac adiponectin and its receptor 1 in type 2 diabetic rats.
P2860
Q24645442-85422A33-381F-4A4F-A461-42D9E739952BQ28536366-2EDBC0C2-75E1-45AB-B6F1-025E78241CA5Q35819219-A223B6AB-7977-497B-B951-0C9B1897F365Q36459419-8E4E7170-1026-47EA-B36B-C99F91DA03DAQ36470320-B5BDA221-447D-4C82-94AF-73802E99DD46Q36484662-F3FF1DF6-A30E-4128-860C-9F08DEFDE10FQ36541439-393107F5-6024-43BE-82E0-E3629E621FD1Q36642651-2E0C41FB-0C61-49A0-ADD9-10F05AE5245AQ36674865-C6A6A3CB-4834-4BFD-AAF4-4C32F1E19CDDQ36676571-2076A16F-8969-4C59-A04A-FC57830EC9D2Q36736724-923CF6B2-4B2E-4046-8265-1C0D8EB4F36FQ36936358-BB319326-EC02-4744-B6DA-C552D34F7E42Q37001374-BE466E61-9866-47A3-8DC5-CBDA636FAF30Q37068534-660C23BB-6BE6-4ABF-AB43-0E4733451CF9Q37104853-C87A2ED3-CC86-4DD3-95FA-3DFB4B565437Q37127287-628D166E-89A1-47B8-86C1-D66BD3C1EAA1Q37141972-6022204D-1F7D-4F21-9879-58BEAF3E5B59Q38071935-995A5FC1-AF9B-4228-8E3A-382F23264C20Q38755925-4908E2D3-D7C2-47DB-A440-947D6EF29637Q39483579-EA466C54-7FC7-41E0-A60D-00423EE0365FQ40073832-9B008554-C25A-4B32-B11D-4AAD2B5559B8Q41835562-0FB15DD4-22FB-4F03-8527-AB2218E2A8BFQ42062446-F7D9B6F3-60CD-41D2-A93F-17D923D66E74Q43235382-E215A074-8984-44F0-B5A8-3C362014AF60Q45378652-BDA9CBAC-9E2C-4C29-95A6-C7C03E5D0AC5Q47367725-56C36750-9801-466D-B8E3-987218352D4CQ53141326-C643ECEB-338B-49AA-8723-4545C18C0E13Q53714410-21399F4B-0A64-4FEB-B17B-3EAD1D388649Q54397507-54D50189-6F6E-4F3B-BDB5-9981799593C4
P2860
Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Treating the metabolic syndrom ...... ated receptor-gamma activator.
@ast
Treating the metabolic syndrom ...... ated receptor-gamma activator.
@en
type
label
Treating the metabolic syndrom ...... ated receptor-gamma activator.
@ast
Treating the metabolic syndrom ...... ated receptor-gamma activator.
@en
prefLabel
Treating the metabolic syndrom ...... ated receptor-gamma activator.
@ast
Treating the metabolic syndrom ...... ated receptor-gamma activator.
@en
P1433
P1476
Treating the metabolic syndrom ...... ated receptor-gamma activator.
@en
P2093
P2888
P356
10.1007/S00592-005-0176-0
P478
42 Suppl 1
P577
2005-04-01T00:00:00Z